<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03279484</url>
  </required_header>
  <id_info>
    <org_study_id>LCPL01</org_study_id>
    <nct_id>NCT03279484</nct_id>
  </id_info>
  <brief_title>Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector</brief_title>
  <acronym>NAVIGATOR</acronym>
  <official_title>Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and electrical performance of
      Left ventricular (LV) NAVIGO 4LV leads, pre-shaped (S-shaped&amp;U-shaped: NAVIGO 4LV 2D, NAVIGO
      4LV ARC) and Straight (NAVIGO 4LV PILOT), with IS4 connector
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The devices under investigation, NAVIGO 4LV models Pilot, 2D , and ARC are the new
      quadripolar coronary venous leads with polyurethane lead body, intended to be used with
      defibrillators with ventricular resynchronization therapy.

      The new lead design with the presence of 4 electrodes that allows several combinations in
      programming pacing vectors, is intended to benefit both the patients by improving response to
      therapy, overcoming high pacing threshold and avoiding phrenic nerve stimulation, and the
      investigators by reducing the number of re-interventions needed.

      This clinical investigation is a pre-market release study intended to analyze safety and
      electrical performance of NAVIGO 4LV leads pre-shaped (S-shaped &amp; U-shaped) and Straight
      leads models. The primary endpoint data will be used to support the achievement of the CE
      mark of NAVIGO 4LV leads.

      The primary endpoints will be evaluated at 1 month post-implantation; secondary endpoints
      will be evaluated up to 2 years post-implantation. The duration of patient inclusion will be
      approximately 4 months for pre-shaped NAVIGO family (S-shaped &amp;U-shaped) and approximately 18
      months for straight ones.

      The post implant follows-up visits will take place at Hospital discharge, 1 month, 6 months
      and every 6 months until 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>NAVIGO 4LV LV leads are available as &quot;S shaped&quot;(NAVIGO 4LV 2D) , &quot;U shaped&quot; (NAVIGO 4LV ARC) and &quot;straight&quot;( NAVIGO 4LV Pilot) models. All the models are available in 78 cm and 88 cm long versions. All models are designed for multipolar pacing (4 electrodes) and all of them have a quadripolar IS4 connector (IS4_LLLL).
The NAVIGO 4LV leads are steroid eluting to avoid adverse effects due to inflammation reaction of the myocardium after positioning of the lead, and therefore to limit the acute pacing threshold peak. The steroid collar design is the same as the one used in all other LIVANOVA leads</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV lead Safety at 1 month</measure>
    <time_frame>1 month after implant</time_frame>
    <description>Freedom from LV lead-related complications, defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming) that occurred within 30 days after successful implant of the CRT-D system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LV lead Performance at 1 month</measure>
    <time_frame>1 month after implant</time_frame>
    <description>Successful performance defined as LV pacing threshold at 1 month &lt; 2.5 V/0.5 ms observed on at least one pacing vector and absence of phrenic nerve stimulation at programmed pacing amplitude</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrical performance</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>LV pacing threshold amplitude (V) and LV pacing impedance (Ohm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients free from LV lead-related complications</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>Freedom from LV lead-related complications defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV lead-related SAEs</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>Serious Adverse Event LV related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead handing assessment of NAVIGO 4LV leads through a questionnaire</measure>
    <time_frame>Implant</time_frame>
    <description>A questionnaire on lead handling will track opinion from the investigator, comparing his assessment with this lead to device he is accustomed to implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAVIGO 4LV lead implant success rate on enrolled population</measure>
    <time_frame>Enrollment</time_frame>
    <description>To report the NAVIGO 4LV lead implant success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with at least 2 pacing vectors with pacing threshold &lt; 2.5 V at 0.5 ms and no phrenic nerve stimulation</measure>
    <time_frame>1 month</time_frame>
    <description>To report the number of patients with at least 2 pacing vectors with pacing threshold &lt; 2.5 V at 0.5 ms and no phrenic nerve stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with MP pacing activated</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>To report the number of patients with MP pacing activated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rationale to activate MP</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>To report the reason why physician decide to activate MP to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with of at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>To report the number of patients with at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients at each final programmed pacing vector and changes</measure>
    <time_frame>through study completion, an average of 6 month</time_frame>
    <description>To report number of patients at each final programmed pacing vector and changes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Arrythmia, Implatable Cardioverter Defibrillation, Lead</condition>
  <arm_group>
    <arm_group_label>NAVIGO 4LV implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be attempted to implant or implanted with NAVIGO 4LV lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAVIGO 4LV lead implant</intervention_name>
    <description>All patients will be attempted to implant or implanted with NAVIGO 4LV lead</description>
    <arm_group_label>NAVIGO 4LV implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient presenting a CRT-D indication as detailed in the ESC guidelines

          -  Primary implant of a PLATINIUM 4LV CRTD or upgrade from an existing ICD connected to a
             RV lead with a DF4 connector (DF4LLHH) to a PLATINIUM 4LV CRT-D

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Patients for whom a maximum single dose of 300 Âµg dexamethasone sodium phosphate (DSP)
             eluted from the NAVIGO 4LV lead maybe contraindicated

          -  Venous anomalies precluding transvenous implant (contraindication of a Pacemaker or
             ICD implant)

          -  Active myocarditis, pocket and/or lead infection

          -  Stroke/myocardiaI infarction one month prior to implant

          -  Already included in another clinical study that could confound the results of this
             study.

          -  Inability to meet Follow-up visits at the implanting centre as defined in the
             investigational plan.

          -  Patient less than 18 years old or under guardianship

          -  Known pregnancy, women in lactation period or in childbearing age without an adequate
             contraceptive method (failure rate &lt; 1%)

          -  Drug addiction or abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Gabriel Martinez Martinez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Alicante Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Martino</last_name>
    <phone>+390161487826</phone>
    <email>maria.martino@livanova.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus-Jurgen GUTLEBEN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Klaus-Jurgen GUTLEBEN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph KLEIN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Christoph KLEIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten ISRAEL, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Carsten ISRAEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhau</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert NAEGELE, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Herbert NAEGELE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik BONNEMEIER, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Hendrik BONNEMEIER, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter NORDBECK, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Peter NORDBECK, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Universitario Di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARIA GRAZIA BONGIORNI, MD</last_name>
      <phone>+39 050 993252</phone>
      <email>m.g.bongiorni@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>MARIA GRAZIA BONGIORNI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ISALA Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>10500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter-Paul DELNOY, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Peter-Paul DELNOY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Ocidental -Hospital de Santa Cruz (CHLO)</name>
      <address>
        <city>Carnaxide</city>
        <zip>2799</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Manuel ADRAGÃO PULIDO GARCIA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Manuel ADRAGÃO PULIDO GARCIA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar UniversitÃ¡rio de Coimbra -Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis ELVAS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Luis ELVAS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e UniversitÃ¡rio de Coimbra - Hospital Geral</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JosÃ© NASCIMENTO, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JosÃ© NASCIMENTO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro H. Lisboa Norte - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao de SOUSA, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Joao de SOUSA, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHCL - Hospital Santa Marta</name>
      <address>
        <city>Lisbon</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario OLIVEIRA, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mario OLIVEIRA, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto CHP Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hipolito REIS, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Hipolito REIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Gabriel MARTINEZ, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Juan Gabriel MARTINEZ, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JosÃ© Manuel RUBIN LOPEZ, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JosÃ© Manuel RUBIN LOPEZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar CANO PEREZ, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Oscar CANO PEREZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo - Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvis TEIJEIRA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Elvis TEIJEIRA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety , electrical performance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

